Pi Therapeutics

About Pi Therapeutics

Pi Therapeutics is a preclinical-stage pharmaceutical company focused on developing modulators of protein degradation for cancer treatment. Established in 2015, the company is headquartered in Ness Ziona, Israel, and operates out of the FutuRx biotech incubator. The firm's scientific foundation is built upon technology in-licensed from Johns Hopkins University.

The company's primary business involves the research and development of novel cancer drugs. Its lead product is a first-in-class inhibitor that modulates pathways related to proteostasis, which is the process of maintaining protein health within a cell. This offers a distinct method for preferentially targeting and inducing cell death in cancerous cells, with preclinical data showing a compelling safety and efficacy profile compared to other protein degradation inhibitors. The therapeutic targets include both liquid and solid tumors. The business model is centered on advancing its lead program through clinical trials to achieve proof-of-concept, which would then likely lead to partnerships or acquisition by larger pharmaceutical companies.

Pi Therapeutics was founded within the FutuRx biotech incubator, which is supported by major pharmaceutical entities like Takeda Pharmaceuticals, Johnson & Johnson, and OrbiMed. The company has successfully raised significant capital to fund its operations. A notable milestone was the completion of a $19.7 million Series B financing round in May 2019, bringing its total funds raised to approximately $24 million at the time. This funding was led by Pontifax and included participation from Quark Venture, GF Securities, Arkin Bio Ventures, and others. The capital is allocated to advancing the lead drug candidate into clinical studies. The company is led by CEO Dr. Ori Kalid.